Unknown

Dataset Information

0

Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.


ABSTRACT: Enzyme replacement therapy (ERT) is the standard-of-care treatment of Pompe disease, a lysosomal storage disorder caused by deficiency of acid ?-glucosidase (GAA). One limitation of ERT with recombinant human (rh) GAA is antibody formation against GAA. Similarly, in adeno-associated virus (AAV) vector-mediated gene transfer for Pompe disease, development of antibodies against the GAA transgene product and the AAV vector prevents therapeutic efficacy and vector readministration, respectively. Here a nondepleting anti-CD4 monoclonal antibody (mAb) was administrated intravenously prior to administration of an AAV2/9 vector encoding GAA to suppress anti-GAA responses, leading to a substantial reduction of anti-GAA immunoglobulins, including IgG1, IgG2a, IgG2b, IgG2c, and IgG3. Transduction efficiency in liver with a subsequent AAV2/8 vector was massively improved by the administration of anti-CD4 mAb with the initial AAV2/9 vector, indicating a spread of benefit derived from control of the immune response to the first AAV2/9 vector. Anti-CD4 mAb along with AAV2/9-CBhGAApA significantly increased GAA activity in heart and skeletal muscles along with a significant reduction of glycogen accumulation. Taken together, these data demonstrated that the addition of nondepleting anti-CD4 mAb with gene therapy controls humoral immune responses to both vector and transgene, resulting in clear therapeutic benefit in mice with Pompe disease.

SUBMITTER: Han SO 

PROVIDER: S-EPMC4303018 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.

Han Sang-oh SO   Li Songtao S   Brooks Elizabeth D ED   Masat Elisa E   Leborgne Christian C   Banugaria Suhrad S   Bird Andrew A   Mingozzi Federico F   Waldmann Herman H   Koeberl Dwight D  

Human gene therapy 20150101 1


Enzyme replacement therapy (ERT) is the standard-of-care treatment of Pompe disease, a lysosomal storage disorder caused by deficiency of acid α-glucosidase (GAA). One limitation of ERT with recombinant human (rh) GAA is antibody formation against GAA. Similarly, in adeno-associated virus (AAV) vector-mediated gene transfer for Pompe disease, development of antibodies against the GAA transgene product and the AAV vector prevents therapeutic efficacy and vector readministration, respectively. Her  ...[more]

Similar Datasets

| S-EPMC3095055 | biostudies-literature
| S-EPMC6642935 | biostudies-literature
| S-EPMC3101281 | biostudies-literature
| S-EPMC6642941 | biostudies-literature
| S-EPMC7029369 | biostudies-literature
| S-EPMC4520217 | biostudies-literature
| S-EPMC6642929 | biostudies-literature
| S-EPMC7240064 | biostudies-literature
| S-EPMC5363303 | biostudies-literature
| S-EPMC4833676 | biostudies-literature